AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

(Reuters) – U.S. regulators have expanded use of AstraZeneca’s lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

Source: Reuters Medical News